Table 2.
Comparison of patients according to the presence of venous thromboembolism
| Baseline characteristics | Non-VTE (N = 52) | VTE (N = 6) | p-value |
|---|---|---|---|
| Median age, years (IQR) | 68 (63–74) | 63 (57–66) | 0.090 |
| Sex | |||
| Male, n (%) | 26 (50) | 4 (67) | 0.671 |
| Female, n (% | 26 (50) | 2 (33) | |
| Previous VTE, n (%) | 10 (19) | 0 | 0.577 |
| Previous therapeutic anticoagulation, n (%) | 10 (19) | 1 (17) | 1.000 |
| Cancer characteristics | Non-VTE (N = 52) | VTE (N = 6) | |
|---|---|---|---|
| Primary tumor, n (%) | |||
| Lung | 14 (27) | 2 (33) | |
| Breast | 9 (17) | 1 (17) | |
| Colorectal | 8 (15) | 0 | |
| Prostate | 4 (8) | 1 (17) | |
| Urothelial | 3 (6) | 0 | |
| Head and neck | 3 (6) | 0 | |
| Pancreatic | 1 (2) | 1 (17) | |
| Ovarian | 2 (3,8) | 0 | |
| Hepatobiliary | 2 (4) | 0 | |
| Metastatic disease, n (%) | 42 (81) | 6 (100) | 0.577 |
| Pulmonary involvement, n (%) | 19 (37) | 3 (50) | 0.664 |
| Treatment, n (%) | |||
| Chemotherapy alone | 22 (42) | 4 (67) | |
| Immunotherapy alone | 9 (17) | 0 | |
| Chemotherapy and immunotherapy | 4 (8) | 1 (17) | |
| Hormonotherapy | 9 (17) | 0 | |
| RET inhibitor | 0 | 1 (17) | |
| Chemotherapy vs. others | 26 (50) | 5 (83) | 0.201 |
| COVID-19 outcomes | Non-VTE (N = 52) | VTE (N = 6) | |
|---|---|---|---|
| Median D-dimer, ng/ml (IQR) | 1610 (695–2620) | 9729 (4120–21,300) | 0.002 |
| Distress, n (%) | 23 (44) | 2 (33) | 0.690 |
| Mortality | Non-VTE (N = 52) | VTE (N = 6) | |
|---|---|---|---|
| Death, n (%) | 17 (33) | 4 (67) | 0.176 |
| COVID-19 related death, n (%) | 16 (31) | 1 (17) | 0.660 |
| Malignancy related death, n (%) | 1 (3) | 3 (60) | 0.004 |
| Bleeding, n (%) | 0 | 0 |
IQR interquartile range, VTE venous thromboembolism